Mortality Data From the BASKET LATE Trial and PREMIER Registry BASKET LATE Trial: Cardiac Death in DES vs. BMS (%) p=0.09 PREMIER Registry Data: All Cause Death According to Minimum 30 day thienopyridine Therapy Duration (%) p<0.0001 % patients % patients In the BASKET LATE Trial, cardiac death trended higher in the DES group than in the BMS group during the year following clopidogrel discontinuation (1.2% vs. 0%, p=0.09). Data from the PREMIER registry looked exclusively at AMI patients who received DES and suggested that patients who discontinued thienopyridine therapy early - within 30 days in this instance - were significantly more likely to die over the next 11 months (p<0.0001).